OTC Medicines

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the following statement today following West Virginia Governor Jim Justice signing Senate Bill (SB) 688 into law. This legislation lifts the annual purchasing limits for common over-the-counter cold and allergy

Washington, D.C. – The annual Monitoring the Future survey (MTF), conducted by researchers at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA), shows that the percentage of adolescents reporting any substance use in 2023 continues to “hold steady” and remains below pre-pandemic levels, including abuse of over-the-counter (OTC) cough & cold medicines.

(Washington, D.C.) – Consumer Healthcare Products Association (CHPA) Senior Vice President of Regulatory and Scientific Affairs Lisa Parks released the following statement today regarding the U.S. Food and Drug Administration’s

CHPA released a statement after submitting a Citizen Petition to the U.S. Federal Trade Commission (FTC) urging it to withdraw the Notice of Penalty Offenses Concerning Substantiation of Product Claims.

CHPA expresses disappointment in the recent NDAC recommendation and encourages FDA to consider the total weight of evidence before making any regulatory changes.

CHPA's most current statement on the recent meeting of the FDA Nonprescription Advisory Committee (NDAC) to evaluate the efficacy of oral phenylephrine (PE).